Citations (72)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (17)
Ray Borrow, Federico Martinón-Torres, Véronique Abitbol, Anar Andani, Scott Preiss, Alessandro Muzzi, Laura Serino & Woo-Yun Sohn. (2023) Use of expanded Neisseria meningitidis serogroup B panels with the serum bactericidal antibody assay for the evaluation of meningococcal B vaccine effectiveness. Expert Review of Vaccines 22:1, pages 738-748.
Read now
Read now
Jessica Presa, Cynthia Burman, Maria J. Tort, Alejandro Cane & Joseph A. Bocchini$suffix/text()$suffix/text(). (2023) Serum bactericidal activity against circulating and reference strains of meningococcal serogroup B in the United States: A review of the strain coverage of meningococcal serogroup B (MenB) vaccines in adolescents and young adults. Human Vaccines & Immunotherapeutics 19:1.
Read now
Read now
Jamie Findlow, Ray Borrow, David S. Stephens, Paul Liberator, Annaliesa S. Anderson, Paul Balmer & Luis Jodar. (2022) Correlates of protection for meningococcal surface protein vaccines: current approaches for the determination of breadth of coverage. Expert Review of Vaccines 21:6, pages 753-769.
Read now
Read now
Jamie Findlow, Jay Lucidarme, Muhamed-Kheir Taha, Cynthia Burman & Paul Balmer. (2022) Correlates of protection for meningococcal surface protein vaccines: lessons from the past. Expert Review of Vaccines 21:6, pages 739-751.
Read now
Read now
Marco Aurelio P. Safadi, Federico Martinón-Torres, Lidia Serra, Cynthia Burman & Jessica Presa. (2021) Translating meningococcal serogroup B vaccines for healthcare professionals. Expert Review of Vaccines 20:4, pages 401-414.
Read now
Read now
Justine Alderfer, Raul E. Isturiz & Amit Srivastava. (2020) Lessons from mass vaccination response to meningococcal B outbreaks at US universities. Postgraduate Medicine 132:7, pages 614-623.
Read now
Read now
Paul Balmer, Johannes Beeslaar, Jamie Findlow & Amit Srivastava. (2020) Understanding immunogenicity assessments for meningococcal serogroup B vaccines. Postgraduate Medicine 132:2, pages 184-191.
Read now
Read now
Irene Rivero-Calle, Peter Francis Raguindin, Jose Gómez-Rial, Carmen Rodriguez-Tenreiro & Federico Martinón-Torres. (2019) Meningococcal Group B Vaccine For The Prevention Of Invasive Meningococcal Disease Caused By Neisseria meningitidis Serogroup B. Infection and Drug Resistance 12, pages 3169-3188.
Read now
Read now
Jamie Findlow, Charles Nuttens & Paula Kriz. (2019) Introduction of a second MenB vaccine into Europe – needs and opportunities for public health. Expert Review of Vaccines 18:3, pages 225-239.
Read now
Read now
John L. Perez, Judith Absalon, Johannes Beeslaar, Paul Balmer, Kathrin U. Jansen, Thomas R. Jones, Shannon Harris, Laura J. York, Qin Jiang, David Radley, Annaliesa S. Anderson, Graham Crowther & Joseph J. Eiden. (2018) From research to licensure and beyond: clinical development of MenB-FHbp, a broadly protective meningococcal B vaccine. Expert Review of Vaccines 17:6, pages 461-477.
Read now
Read now
N. Y. Wang & A. J. Pollard. (2018) The next chapter for group B meningococcal vaccines. Critical Reviews in Microbiology 44:1, pages 95-111.
Read now
Read now
Daniela Toneatto, Mariagrazia Pizza, Vega Masignani & Rino Rappuoli. (2017) Emerging experience with meningococcal serogroup B protein vaccines. Expert Review of Vaccines 16:5, pages 433-451.
Read now
Read now
Robert G. K. Donald, Julio Cesar Hawkins, Li Hao, Paul Liberator, Thomas R. Jones, Shannon L. Harris, John L. Perez, Joseph J. Eiden, Kathrin U. Jansen & Annaliesa S. Anderson. (2017) Meningococcal serogroup B vaccines: Estimating breadth of coverage. Human Vaccines & Immunotherapeutics 13:2, pages 255-265.
Read now
Read now
Ashesh Gandhi, Paul Balmer & Laura J. York. (2016) Characteristics of a new meningococcal serogroup B vaccine, bivalent rLP2086 (MenB-FHbp; Trumenba®). Postgraduate Medicine 128:6, pages 548-556.
Read now
Read now
Aia Assaf-Casals & Ghassan Dbaibo. (2016) Meningococcal quadrivalent tetanus toxoid conjugate vaccine (MenACWY-TT, Nimenrix™): A review of its immunogenicity, safety, co-administration, and antibody persistence. Human Vaccines & Immunotherapeutics 12:7, pages 1825-1837.
Read now
Read now
Danilo Donnarumma, Agnese Faleri, Paolo Costantino, Rino Rappuoli & Nathalie Norais. (2016) The role of structural proteomics in vaccine development: recent advances and future prospects. Expert Review of Proteomics 13:1, pages 55-68.
Read now
Read now
Kate L Seib, Maria Scarselli, Maurizio Comanducci, Daniela Toneatto & Vega Masignani. (2015) Neisseria meningitidis factor H-binding protein fHbp: a key virulence factor and vaccine antigen. Expert Review of Vaccines 14:6, pages 841-859.
Read now
Read now
Articles from other publishers (55)
Ana Paula Cassiolato, Carlos Henrique Camargo, Maria Cristina Piccoli Cecconi, Sandra Christakis, Claudia Regina Gonçalves, Karoline Rodrigues Campos, Fabio Takenori Higa, Gabriela Andrade Pereira, Camile de Moraes & Ana Paula Silva de Lemos. (2023) Genomic characterization of invasive meningococcal X isolates from Brazil, 1992–2022. International Microbiology 26:3, pages 611-618.
Crossref
Crossref
Helen S Marshall, Timo Vesikari, Peter C Richmond, Jacek Wysocki, Leszek Szenborn, Johannes Beeslaar, Jason D Maguire, Paul Balmer, Robert O'Neill, Annaliesa S Anderson, Jean-Louis Prégaldien, Roger Maansson, Han-Qing Jiang & John L Perez. (2023) Safety and immunogenicity of a primary series and booster dose of the meningococcal serogroup B-factor H binding protein vaccine (MenB-FHbp) in healthy children aged 1–9 years: two phase 2 randomised, controlled, observer-blinded studies. The Lancet Infectious Diseases 23:1, pages 103-116.
Crossref
Crossref
David S. Stephens, Dan M. Granoff, Andrew J. Pollard & Lee H. Harrison. 2023. Plotkin's Vaccines. Plotkin's Vaccines
690
710.e7
.
Chun-Mien Chang, Amaka M. Awanye, Leanne Marsay, Christina Dold, Andrew J. Pollard, Christine S. Rollier, Ian M. Feavers, Martin C.J. Maiden & Jeremy P. Derrick. (2022) Application of a Neisseria meningitidis antigen microarray to identify candidate vaccine proteins from a human Phase I clinical trial. Vaccine 40:28, pages 3835-3842.
Crossref
Crossref
Ala-Eddine Deghmane, Samy Taha & Muhamed-Kheir Taha. (2022) La vaccination contre les infections invasives à méningocoque. Revue Francophone des Laboratoires 2022:540, pages 53-60.
Crossref
Crossref
Daniele Veggi, Enrico Malito, Paola Lo Surdo, Werner Pansegrau, Valentina Rippa, Newton Wahome, Silvana Savino, Vega Masignani, Mariagrazia Pizza & Matthew J. Bottomley. (2022) Structural characterization of a cross-protective natural chimera of factor H binding protein from meningococcal serogroup B strain NL096. Computational and Structural Biotechnology Journal 20, pages 2070-2081.
Crossref
Crossref
Helen S Marshall & Martin C J Maiden. (2021) Impact of a Meningococcal Protein-based Serogroup B Vaccine on Serogroup W Invasive Disease in Children. Clinical Infectious Diseases 73:7, pages e1669-e1672.
Crossref
Crossref
Henju Marjuki, How-Yi Chang, Nadav Topaz, Melissa J. Whaley, Jeni Vuong, Alexander Chen, Laurel T. Jenkins, Fang Hu, Susanna Schmink, Adam C. Retchless, Jennifer D. Thomas, Anna M. Acosta, Lucy A. McNamara, Heidi M. Soeters, Sarah Mbaeyi & Xin Wang. (2021) Genetic Diversity of Meningococcal Serogroup B Vaccine Antigens among Carriage Isolates Collected from Students at Three Universities in the United States, 2015–2016. mBio 12:3.
Crossref
Crossref
G. Tzanakaki, A. Xirogianni, A. Tsitsika, S.A. Clark, K. Kesanopoulos, H.B. Bratcher, A. Papandreou, C.M.C. Rodrigues, M.C.J. Maiden, R. Borrow & M. Tsolia. (2021) Estimated strain coverage of serogroup B meningococcal vaccines: A retrospective study for disease and carrier strains in Greece (2010–2017). Vaccine 39:11, pages 1621-1630.
Crossref
Crossref
Ana Paula Silva de Lemos, Claudio Tavares Sacchi, Claudia Regina Gonçalves, Carlos Henrique Camargo & Ana Lúcia Andrade. (2020) Genomic surveillance of Neisseria meningitidis serogroup B invasive strains: Diversity of vaccine antigen types, Brazil, 2016-2018. PLOS ONE 15:12, pages e0243375.
Crossref
Crossref
Jamie Findlow, Christopher D. Bayliss, Peter T. Beernink, Ray Borrow, Paul Liberator & Paul Balmer. (2020) Broad vaccine protection against Neisseria meningitidis using factor H binding protein. Vaccine 38:49, pages 7716-7727.
Crossref
Crossref
Johannes Beeslaar, Judith Absalon, Annaliesa S. Anderson, Joseph J. Eiden, Paul Balmer, Shannon L. Harris, Thomas R. Jones, Robert E. O’Neill, Jean-Louis Pregaldien, David Radley, Roger Maansson, John Ginis, Amit Srivastava & John L. Perez. (2020) MenB-FHbp Vaccine Protects Against Diverse Meningococcal Strains in Adolescents and Young Adults: Post Hoc Analysis of Two Phase 3 Studies. Infectious Diseases and Therapy 9:3, pages 641-656.
Crossref
Crossref
Cynthia Burman, Justine Alderfer & Vincenza T. Snow. (2019) A review of the immunogenicity, safety and current recommendations for the meningococcal serogroup B vaccine, MenB‐FHbp. Journal of Clinical Pharmacy and Therapeutics 45:2, pages 270-281.
Crossref
Crossref
Julie A. Bettinger, Paul Liberator, Scott A. Halperin, Wendy Vaudry, Manish Sadarangani, Li Hao, Nathaniel Lambert, Kathrin U. Jansen, Annaliesa S. Anderson & Raymond Tsang. (2020) Estimated susceptibility of Canadian meningococcal B isolates to a meningococcal serogroup B vaccine (MenB-FHbp). Vaccine 38:8, pages 2026-2033.
Crossref
Crossref
A. Brik, A. Terrade, E. Hong, A. Deghmane, M.K. Taha, A. Bouafsoun, M. Khmiri, K. Boussetta, S. Boukhir, N. Ben Jaballah, A. Kechrid & H. Smaoui. (2020) Phenotypic and genotypic characterization of meningococcal isolates in Tunis, Tunisia: High diversity and impact on vaccination strategies. International Journal of Infectious Diseases 91, pages 73-78.
Crossref
Crossref
Shannon L. Harris, Cuiwen Tan, John Perez, David Radley, Kathrin U. Jansen, Annaliesa S. Anderson & Thomas R. Jones. (2020) Selection of diverse strains to assess broad coverage of the bivalent FHbp meningococcal B vaccine. npj Vaccines 5:1.
Crossref
Crossref
Brahim Benyahia, Larissa Pereira Brumano, Adalberto Pessoa & Francisco Vitor Santos da Silva. 2020. New and Future Developments in Microbial Biotechnology and Bioengineering. New and Future Developments in Microbial Biotechnology and Bioengineering
31
68
.
Ronni A. G. da Silva, Andrey V. Karlyshev, Neil J. Oldfield, Karl G. Wooldridge, Christopher D. Bayliss, Ali Ryan & Ruth Griffin. (2019) Variant Signal Peptides of Vaccine Antigen, FHbp, Impair Processing Affecting Surface Localization and Antibody-Mediated Killing in Most Meningococcal Isolates. Frontiers in Microbiology 10.
Crossref
Crossref
How-Yi Chang, Jeni Vuong, Fang Hu, Paul Liberator, Alex Chen, Cecilia B. Kretz, Amy Blain, Li Hao, Adam C. Retchless, Melissa J. Whaley, Annaliesa S. Anderson & Xin Wang. (2019) Distribution of Neisseria meningitidis serogroup b (NmB) vaccine antigens in meningococcal disease causing isolates in the United States during 2009–2014, prior to NmB vaccine licensure. Journal of Infection 79:5, pages 426-434.
Crossref
Crossref
Henju Marjuki, Nadav Topaz, Sandeep J. Joseph, Kim M. Gernert, Ellen N. Kersh & Xin Wang. (2019) Genetic Similarity of Gonococcal Homologs to Meningococcal Outer Membrane Proteins of Serogroup B Vaccine. mBio 10:5.
Crossref
Crossref
Timo Vesikari, Lars Østergaard, Johannes Beeslaar, Judith Absalon, Joseph J. Eiden, Kathrin U. Jansen, Thomas R. Jones, Shannon L. Harris, Roger Maansson, Samantha Munson, Robert E. O'Neill, Laura J. York & John L. Perez. (2019) Persistence and 4-year boosting of the bactericidal response elicited by two- and three-dose schedules of MenB-FHbp: A phase 3 extension study in adolescents. Vaccine 37:12, pages 1710-1719.
Crossref
Crossref
T. Tenenbaum, W. Hellenbrand & H. Schroten. (2019) Impfstoffe gegen Meningokokken für das KindesalterVaccines against meningococci for children. Monatsschrift Kinderheilkunde 167:3, pages 196-205.
Crossref
Crossref
Martin Christopher James Maiden. (2019) The Impact of Nucleotide Sequence Analysis on Meningococcal Vaccine Development and Assessment. Frontiers in Immunology 9.
Crossref
Crossref
Shannon L. Harris, Cuiwen Tan, Lubomira Andrew, Li Hao, Paul A. Liberator, Judith Absalon, Annaliesa S. Anderson & Thomas R. Jones. (2018) The bivalent factor H binding protein meningococcal serogroup B vaccine elicits bactericidal antibodies against representative non-serogroup B meningococci. Vaccine 36:45, pages 6867-6874.
Crossref
Crossref
Paul Balmer & Laura J. York. (2018) Optimal use of meningococcal serogroup B vaccines: moving beyond outbreak control. Therapeutic Advances in Vaccines and Immunotherapy 6:3, pages 49-60.
Crossref
Crossref
Johannes Beeslaar, Judith Absalon, Paul Balmer, Amit Srivastava, Roger Maansson, Laura J. York & John L. Perez. (2018) Clinical data supporting a 2-dose schedule of MenB-FHbp, a bivalent meningococcal serogroup B vaccine, in adolescents and young adults. Vaccine 36:28, pages 4004-4013.
Crossref
Crossref
Lisa K. McNeil, Robert G. K. Donald, Alexey Gribenko, Roger French, Nathaniel Lambert, Shannon L. Harris, Thomas R. Jones, Sheng Li, Gary Zlotnick, Ulrich Vogel, Heike Claus, Raquel Abad, Julio A. Vazquez, Ray Borrow, Jamie Findlow, Muhamed-Kheir Taha, Ala-Eddine Deghmane, Dominique A. Caugant, Paula Kriz, Martin Musilek, Xin Wang, Jeni Vuong, Leonard W. Mayer, Michael W. Pride, Kathrin U. Jansen & Annaliesa S. Anderson. (2018) Predicting the Susceptibility of Meningococcal Serogroup B Isolates to Bactericidal Antibodies Elicited by Bivalent rLP2086, a Novel Prophylactic Vaccine. mBio 9:2.
Crossref
Crossref
Li Hao, Matthew T. G. Holden, Xin Wang, Lubomira Andrew, Sabine Wellnitz, Fang Hu, Melissa Whaley, Scott Sammons, Kristen Knipe, Mike Frace, Lucy A. McNamara, Paul Liberator & Annaliesa S. Anderson. (2018) Distinct evolutionary patterns of Neisseria meningitidis serogroup B disease outbreaks at two universities in the USA. Microbial Genomics 4:4.
Crossref
Crossref
Matt Shirley & Muhamed-Kheir Taha. (2018) MenB-FHbp Meningococcal Group B Vaccine (Trumenba®): A Review in Active Immunization in Individuals Aged ≥ 10 Years. Drugs 78:2, pages 257-268.
Crossref
Crossref
Charlene M. C. Rodrigues, Hannah Chan, Caroline Vipond, Keith Jolley, Odile B. Harrison, Jun Wheeler, Gail Whiting, Ian M. Feavers & Martin C. J. Maiden. (2019) Typing complex meningococcal vaccines to understand diversity and population structure of key vaccine antigens. Wellcome Open Research 3, pages 151.
Crossref
Crossref
Charlene M. C. Rodrigues, Hannah Chan, Caroline Vipond, Keith Jolley, Odile B. Harrison, Jun Wheeler, Gail Whiting, Ian M. Feavers & Martin C. J. Maiden. (2018) Typing complex meningococcal vaccines to understand diversity and population structure of key vaccine antigens. Wellcome Open Research 3, pages 151.
Crossref
Crossref
Dan M. Granoff, Andrew J. Pollard & Lee H. Harrison. 2018. Plotkin's Vaccines. Plotkin's Vaccines
644
662.e6
.
Hari Pujar & Mats Lundgren. 2018. Biopharmaceutical Processing. Biopharmaceutical Processing
877
898
.
Lars OstergaardTimo VesikariJudith AbsalonJohannes BeeslaarBrian J. WardShelly SendersJoseph J. EidenKathrin U. JansenAnnaliesa S. AndersonLaura J. YorkThomas R. JonesShannon L. HarrisRobert O’NeillDavid RadleyRoger MaanssonJean-Louis PrégaldienJohn GinisNina B. StaerkeJohn L. Perez. (2017) A Bivalent Meningococcal B Vaccine in Adolescents and Young Adults. New England Journal of Medicine 377:24, pages 2349-2362.
Crossref
Crossref
Eduardo LujanKathleen Winter, Jillandra Rovaris, Qin Liu & Dan M Granoff. (2017) Serum Bactericidal Antibody Responses of Students Immunized With a Meningococcal Serogroup B Vaccine in Response to an Outbreak on a University Campus. Clinical Infectious Diseases 65:7, pages 1112-1119.
Crossref
Crossref
Eduardo Lujan, Elizabeth Partridge, Serena Giuntini, Sanjay Ram & Dan M. Granoff. (2017) Breadth and Duration of Meningococcal Serum Bactericidal Activity in Health Care Workers and Microbiologists Immunized with the MenB-FHbp Vaccine. Clinical and Vaccine Immunology 24:8.
Crossref
Crossref
Liliana Costoya, Juan Marzoa, Carlos Ferreirós & Maria Teresa Criado. (2017)
Liposomes or traditional adjuvants: induction of bactericidal activity by the macrophage infectivity potentiator protein (Mip) of
Neisseria meningitidis
. APMIS 125:8, pages 725-731.
Crossref
Crossref
Thomas Harder, Judith Koch, Ole Wichmann & Wiebke Hellenbrand. (2017) Predicted vs observed effectiveness of outer membrane vesicle (OMV) vaccines against meningococcal serogroup B disease: Systematic review. Journal of Infection 75:2, pages 81-94.
Crossref
Crossref
Muhamed-Kheir Taha, Julio Cesar Hawkins, Paul Liberator, Ala-Eddine Deghmane, Lubomira Andrew, Li Hao, Thomas R. Jones, Lisa K. McNeil, Robert E. O’Neill, John L. Perez, Kathrin U. Jansen & Annaliesa S. Anderson. (2017) Bactericidal activity of sera from adolescents vaccinated with bivalent rLP2086 against meningococcal serogroup B outbreak strains from France. Vaccine 35:11, pages 1530-1537.
Crossref
Crossref
Shannon L. Harris, Robert G. K. Donald, Julio Cesar Hawkins, Cuiwen Tan, Robert O’Neill, Lisa K. McNeil, John L. Perez, Annaliesa S. Anderson, Kathrin U. Jansen & Thomas R. Jones. (2017) Neisseria meningitidis Serogroup B Vaccine, Bivalent rLP2086, Induces Broad Serum Bactericidal Activity Against Diverse Invasive Disease Strains Including Outbreak Strains. Pediatric Infectious Disease Journal 36:2, pages 216-223.
Crossref
Crossref
Helen S Marshall, Peter C Richmond, Johannes Beeslaar, Qin Jiang, Kathrin U Jansen, Maria Garcés-Sánchez, Federico Martinón-Torres, Leszek Szenborn, Jacek Wysocki, Joseph Eiden, Shannon L Harris, Thomas R Jones, Su-San Lee & John L Perez. (2017) Meningococcal serogroup B-specific responses after vaccination with bivalent rLP2086: 4 year follow-up of a randomised, single-blind, placebo-controlled, phase 2 trial. The Lancet Infectious Diseases 17:1, pages 58-67.
Crossref
Crossref
Derek Muse, Shane Christensen, Prakash Bhuyan, Judith Absalon, Joseph J. Eiden, Thomas R. Jones, Laura J. York, Kathrin U. Jansen, Robert E. O’Neill, Shannon L. Harris & John L. Perez. (2016) A Phase 2, Randomized, Active-controlled, Observer-blinded Study to Assess the Immunogenicity, Tolerability and Safety of Bivalent rLP2086, a Meningococcal Serogroup B Vaccine, Coadministered With Tetanus, Diphtheria and Acellular Pertussis Vaccine and Serogroup A, C, Y and W-135 Meningococcal Conjugate Vaccine in Healthy US Adolescents. The Pediatric Infectious Disease Journal 35:6, pages 673-682.
Crossref
Crossref
Timo Vesikari, Jacek Wysocki, Johannes Beeslaar, Joseph Eiden, Qin Jiang, Kathrin U. Jansen, Thomas R. Jones, Shannon L. Harris, Robert E. O'Neill, Laura J. York & John L. Perez. (2016) Immunogenicity, Safety, and Tolerability of Bivalent rLP2086 Meningococcal Group B Vaccine Administered Concomitantly With Diphtheria, Tetanus, and Acellular Pertussis and Inactivated Poliomyelitis Vaccines to Healthy Adolescents. Journal of the Pediatric Infectious Diseases Society 5:2, pages 180-187.
Crossref
Crossref
Timo Vesikari, Lars Østergaard, Javier Diez-Domingo, Jacek Wysocki, Carl-Erik Flodmark, Johannes Beeslaar, Joseph Eiden, Qin Jiang, Kathrin U. Jansen, Thomas R. Jones, Shannon L. Harris, Robert E. O'Neill, Laura J. York, Graham Crowther & John L. Perez. (2016) Meningococcal Serogroup B Bivalent rLP2086 Vaccine Elicits Broad and Robust Serum Bactericidal Responses in Healthy Adolescents. Journal of the Pediatric Infectious Diseases Society 5:2, pages 152-160.
Crossref
Crossref
Saber Yezli, Abdulaziz A. Bin Saeed, Abdullah M. Assiri, Rafat F. Alhakeem, Muslim A. Yunus, Abdulhafiz M. Turkistani, Robert Booy & Badriah M. Alotaibi. (2016) Prevention of meningococcal disease during the Hajj and Umrah mass gatherings: past and current measures and future prospects. International Journal of Infectious Diseases 47, pages 71-78.
Crossref
Crossref
Shelly Senders, Prakash Bhuyan, Qin Jiang, Judith Absalon, Joseph J. Eiden, Thomas R. Jones, Laura J. York, Kathrin U. Jansen, Robert E. O’Neill, Shannon L. Harris, John Ginis & John L. Perez. (2016) Immunogenicity, Tolerability and Safety in Adolescents of Bivalent rLP2086, a Meningococcal Serogroup B Vaccine, Coadministered with Quadrivalent Human Papilloma Virus Vaccine. Pediatric Infectious Disease Journal 35:5, pages 548-554.
Crossref
Crossref
David M. Reiner, Prakash Bhuyan, Joseph J. Eiden, John Ginis, Shannon Harris, Kathrin U. Jansen, Qin Jiang, Thomas R. Jones, Robert E. O’Neill, Laura J. York & John L. Perez. (2016) Immunogenicity, safety, and tolerability of the meningococcal serogroup B bivalent rLP2086 vaccine in adult laboratory workers. Vaccine 34:6, pages 809-813.
Crossref
Crossref
C. Hal Jones, Naglaa Mohamed, Eduardo Rojas, Lubomira Andrew, Johanna Hoyos, Julio C. Hawkins, Lisa K. McNeil, Qin Jiang, Leonard W. Mayer, Xin Wang, Rodica Gilca, Philippe De Wals, Louise Pedneault, Joseph Eiden, Kathrin U. Jansen & Annaliesa S. Anderson. (2016) Comparison of Phenotypic and Genotypic Approaches to Capsule Typing of Neisseria meningitidis by Use of Invasive and Carriage Isolate Collections. Journal of Clinical Microbiology 54:1, pages 25-34.
Crossref
Crossref
Rolando Pajon, Eduardo Lujan & Dan M. Granoff. (2016) A meningococcal NOMV-FHbp vaccine for Africa elicits broader serum bactericidal antibody responses against serogroup B and non-B strains than a licensed serogroup B vaccine. Vaccine 34:5, pages 643-649.
Crossref
Crossref
Andrew R Gorringe. (2016) The difficult road to new vaccines for pertussis and serogroup B meningococcal disease. Journal of Chemical Technology & Biotechnology 91:1, pages 9-15.
Crossref
Crossref
Matt Shirley & Sohita Dhillon. (2015) Bivalent rLP2086 Vaccine (Trumenba®): A Review in Active Immunization Against Invasive Meningococcal Group B Disease in Individuals Aged 10–25 Years. BioDrugs 29:5, pages 353-361.
Crossref
Crossref
Eduardo Rojas, Johanna Hoyos, Neil J. Oldfield, Philip Lee, Mike Flint, C. Hal Jones, Dlawer A. A. Ala’Aldeen, Kathrin U. Jansen & Annaliesa S. Anderson. (2015) Optimization of Molecular Approaches to Genogroup Neisseria meningitidis Carriage Isolates and Implications for Monitoring the Impact of New Serogroup B Vaccines. PLOS ONE 10:7, pages e0132140.
Crossref
Crossref
Christopher B. Wilson & Christopher L. Karp. (2015) Can immunological principles and cross-disciplinary science illuminate the path to vaccines for HIV and other global health challenges?. Philosophical Transactions of the Royal Society B: Biological Sciences 370:1671, pages 20140152.
Crossref
Crossref
Enrico Malito, Andrea Carfi & Matthew Bottomley. (2015) Protein Crystallography in Vaccine Research and Development. International Journal of Molecular Sciences 16:12, pages 13106-13140.
Crossref
Crossref
Susanna Esposito, Claudia Tagliabue & Samantha Bosis. (2015) Meningococcal B Vaccination (4CMenB) in Infants and Toddlers. Journal of Immunology Research 2015, pages 1-6.
Crossref
Crossref